{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urethritis-male/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"c498c9de-1083-50a6-b290-ac30aebda851","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 003b7274-aa48-4b3a-95b9-748330929fd3 --><h2>Azithromycin</h2><!-- end field 003b7274-aa48-4b3a-95b9-748330929fd3 -->","summary":"","htmlStringContent":"<!-- begin item 1db84d35-55c6-42f1-a44a-7f4feede38bf --><!-- end item 1db84d35-55c6-42f1-a44a-7f4feede38bf -->","topic":{"id":"f36465a1-1338-5604-8bb2-c8e555c598ae","topicId":"9d634e3c-7474-4d96-bbcb-7c29c10c1b03","topicName":"Urethritis - male","slug":"urethritis-male","lastRevised":"Last revised in September 2019","chapters":[{"id":"ac50911c-3aae-5117-95ce-67557d49723a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ae05a825-47bf-5fc0-9065-c859d8427b3b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1c94ea5f-b73f-51a3-9d99-83814d055e3f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e3d5f57-add8-5b6f-bd13-9ea05bc5ec30","slug":"changes","fullItemName":"Changes"},{"id":"7353c5be-d0ed-506f-8487-265ce270e97f","slug":"update","fullItemName":"Update"}]},{"id":"644de86f-bfeb-5ebf-8cda-c1be15f8938a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bd23c29c-af09-54b6-be4e-9f6ed812d62a","slug":"goals","fullItemName":"Goals"},{"id":"63346f4c-c71f-5887-b6d3-0d07661b1393","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49121260-b8cb-5ecc-855a-f87303bc727e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"40b6a387-e841-594d-8616-fb4e8f4391e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d3a51c9-f614-5196-8052-55ceb4b6cf08","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b2b68ef0-16c8-5dbc-b8f8-fbdfa673ed3f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"027c2bf3-1625-560c-902b-9fef54935849","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"95898c97-d200-5648-b696-7388ab850318","slug":"definition","fullItemName":"Definition"},{"id":"9b0e6aa9-b665-52de-bfa3-93f09f83bc3d","slug":"causes","fullItemName":"Causes"},{"id":"f9c36294-6c74-5b9e-8afb-65b38bfa14e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2d0fc428-15ca-543a-bd93-b4ac231ed0cb","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b7be062a-0eff-5e83-9493-809927e4776a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"60b1f452-fec4-567e-b8f0-39660841e61b","slug":"when-to-suspect-urethritis","fullItemName":"When to suspect urethritis"},{"id":"d5d984a2-a3d7-533a-9b94-02ac51c4fa07","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"75471ada-cb93-59f3-97b0-3c182e9f80b7","fullItemName":"Management","slug":"management","subChapters":[{"id":"b6607a10-84f2-51a2-ac03-a68ccb8dcbe9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6598b6d1-3e66-518c-9a8b-63eff17fecaf","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"c498c9de-1083-50a6-b290-ac30aebda851","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"ecf258dc-1499-5f7a-a781-6566ea1a4f54","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"f4c18a1e-b367-5433-ac91-efd9bce81a5e","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"221c9f46-f915-5e6f-8275-959420090646","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25917416-1fc8-5919-9773-f3b7e054b6a0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2ad44d6a-7cb1-598d-9dd4-9552f4f7fb49","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"791a5ccc-3882-5e9e-a55e-fc18bff5d67a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7370a44f-6a25-58d8-a772-568023fd6516","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"991288b5-d1b7-50f9-8e87-ceaf3331e0e2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf8f6743-57dd-5f6e-9460-bbecad8fd0b5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b2d086b7-cf3d-5d24-994a-e0280f2397db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"163ddceb-973c-5dcc-914d-99d27ba75fab","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f1cc51e7-4bfe-4504-b805-d43410ec2df3 --><h3>Contraindications and cautions</h3><!-- end field f1cc51e7-4bfe-4504-b805-d43410ec2df3 -->","summary":"","htmlStringContent":"<!-- begin item baaca25b-41eb-40c1-8992-f9407ec02f08 --><!-- begin field 456f3879-9153-4cf9-899b-8629ad410dd6 --><p><strong>Use azithromycin with caution in people: </strong></p><ul><li><strong>Who may be predisposed to prolongation of the QT interval. This includes people:</strong><ul><li>With congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency.</li></ul></li><li><strong>With significant hepatic disease or who are talking other hepatotoxic medicines.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 456f3879-9153-4cf9-899b-8629ad410dd6 --><!-- end item baaca25b-41eb-40c1-8992-f9407ec02f08 -->","subChapters":[]},{"id":"f96506b6-69df-50b4-8ea9-0599dc71bd4f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field db7dd70f-009e-472f-b34d-bd5558c29bfd --><h3>Adverse effects</h3><!-- end field db7dd70f-009e-472f-b34d-bd5558c29bfd -->","summary":"","htmlStringContent":"<!-- begin item ef86e7eb-d6ad-4c13-8834-3c7aebc0facf --><!-- begin field 246fec32-4a71-4777-91aa-3db128bc22a3 --><ul><li>Nausea, vomiting, diarrhoea, and abdominal discomfort are the most common adverse effects of all the macrolides, but are milder and less frequent with azithromycin than with erythromycin.</li><li>Drug reaction with eosinophilia and systemic symptoms (DRESS) occurs very rarely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 246fec32-4a71-4777-91aa-3db128bc22a3 --><!-- end item ef86e7eb-d6ad-4c13-8834-3c7aebc0facf -->","subChapters":[]},{"id":"4c87e09d-180f-5101-98ec-3af12e55a0f3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 560d0456-f3dd-4df8-912e-d90c97640e4d --><h3>Drug interactions</h3><!-- end field 560d0456-f3dd-4df8-912e-d90c97640e4d -->","summary":"","htmlStringContent":"<!-- begin item 3e6dbdb3-4b0a-4d24-8929-85a43e17ab22 --><!-- begin field 1e9ca875-7b2b-40ca-ac53-a44f45263ed4 --><ul><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— the manufacturer reports post-marketing cases of rhabdomyolysis in people taking azithromycin with statins, although this appears to be less common than with other macrolides.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Ciclosporin </strong>— azithromycin can affect clearance of ciclosporin.<ul><li>If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-<sub>2</sub> agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Colchicine </strong>—  concomitant administration has been reported to increase levels of P-glycoprotein substrate. This protein has been linked to barriers to successful chemotherapy treatment in cancer.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 1e9ca875-7b2b-40ca-ac53-a44f45263ed4 --><!-- end item 3e6dbdb3-4b0a-4d24-8929-85a43e17ab22 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}